Kidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses
Journal of the American College of Cardiology (JACC)
•
June 02, 2026
Semaglutide improves kidney outcomes in diabetic kidney disease
Weekly semaglutide lowered serious kidney outcomes and death in type 2 diabetes with chronic kidney disease, with similar benefit across baseline cardiovascular risk groups. *Randomized trial subgroup analysis; Level 2b (OCEBM).
- Level of evidence
- Level 2b (OCEBM)
- DocG quality score
- 7.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
